342 related articles for article (PubMed ID: 28855981)
1. Role of BACE1 in Alzheimer's synaptic function.
Das B; Yan R
Transl Neurodegener; 2017; 6():23. PubMed ID: 28855981
[TBL] [Abstract][Full Text] [Related]
2. Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs.
Yan R
Transl Neurodegener; 2016; 5():13. PubMed ID: 27418961
[TBL] [Abstract][Full Text] [Related]
3. Physiological Functions of the β-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2.
Yan R
Front Mol Neurosci; 2017; 10():97. PubMed ID: 28469554
[TBL] [Abstract][Full Text] [Related]
4. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis.
Deng Y; Wang Z; Wang R; Zhang X; Zhang S; Wu Y; Staufenbiel M; Cai F; Song W
Eur J Neurosci; 2013 Jun; 37(12):1962-9. PubMed ID: 23773065
[TBL] [Abstract][Full Text] [Related]
5. BACE1: the beta-secretase enzyme in Alzheimer's disease.
Vassar R
J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
[TBL] [Abstract][Full Text] [Related]
6. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
Vassar R
J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
8. Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment.
Coimbra JRM; Marques DFF; Baptista SJ; Pereira CMF; Moreira PI; Dinis TCP; Santos AE; Salvador JAR
Front Chem; 2018; 6():178. PubMed ID: 29881722
[TBL] [Abstract][Full Text] [Related]
9. BACE1 in Alzheimer's disease.
Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
[TBL] [Abstract][Full Text] [Related]
10. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease.
Hampel H; Shen Y
Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117
[TBL] [Abstract][Full Text] [Related]
11. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
[TBL] [Abstract][Full Text] [Related]
12. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
Wu G; Sankaranarayanan S; Hsieh SH; Simon AJ; Savage MJ
J Neurosci Res; 2011 Jun; 89(6):822-32. PubMed ID: 21433051
[TBL] [Abstract][Full Text] [Related]
13. Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes.
Sun X; Wang Y; Qing H; Christensen MA; Liu Y; Zhou W; Tong Y; Xiao C; Huang Y; Zhang S; Liu X; Song W
FASEB J; 2005 May; 19(7):739-49. PubMed ID: 15857888
[TBL] [Abstract][Full Text] [Related]
14. β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer's disease.
Menting KW; Claassen JA
Front Aging Neurosci; 2014; 6():165. PubMed ID: 25100992
[TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
16. Alzheimer's therapy targeting the β-secretase enzyme BACE1: Benefits and potential limitations from the perspective of animal model studies.
Ohno M
Brain Res Bull; 2016 Sep; 126(Pt 2):183-198. PubMed ID: 27093940
[TBL] [Abstract][Full Text] [Related]
17. Swedish mutant APP-based BACE1 binding site peptide reduces APP β-cleavage and cerebral Aβ levels in Alzheimer's mice.
Li S; Hou H; Mori T; Sawmiller D; Smith A; Tian J; Wang Y; Giunta B; Sanberg PR; Zhang S; Tan J
Sci Rep; 2015 Jun; 5():11322. PubMed ID: 26091071
[TBL] [Abstract][Full Text] [Related]
18. Camelid heavy chain only antibody fragment domain against β-site of amyloid precursor protein cleaving enzyme 1 inhibits β-secretase activity in vitro and in vivo.
Dorresteijn B; Rotman M; Faber D; Schravesande R; Suidgeest E; van der Weerd L; van der Maarel SM; Verrips CT; El Khattabi M
FEBS J; 2015 Sep; 282(18):3618-31. PubMed ID: 26147692
[TBL] [Abstract][Full Text] [Related]
19. beta-Secretase, APP and Abeta in Alzheimer's disease.
Vassar R
Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
[TBL] [Abstract][Full Text] [Related]
20. Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer's disease.
Goozee KG; Shah TM; Sohrabi HR; Rainey-Smith SR; Brown B; Verdile G; Martins RN
Br J Nutr; 2016 Feb; 115(3):449-65. PubMed ID: 26652155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
